[Featured Stock] SK Bioscience Rises on US Clinical Phase 3 Approval for Pneumococcal Vaccine
Up 4.24% Compared to Previous Close
SK Bioscience is showing strong performance in early trading on the 20th following news that it has received approval for the Phase 3 clinical trial plan of its 21-valent pneumococcal vaccine (GBP410) in the United States.
As of 10:09 AM on the same day, SK Bioscience is trading at 51,600 KRW, up 4.24% from the previous close.
Hot Picks Today
“Washing Dishes and Folding Clothes 200 Times a Day”... China’s “Robot Trainers” Earn Up to 1.2 Million Won a Month
- "Even New York Taxi Drivers Are Talking About the KOSPI; South Korean Market to Top 9,000 Again Within a Year"... 'Wall Street's Stock-Picking Ace' Names His Picks
- “Made 2 Billion Won in One Year in Prison,” PPP Lawmaker Retorts: “If You’re Jealous, Go There Yourself”
- City Bus Driver Who Fell Asleep at the Wheel While 'Drunk' Bought Meth via 'Drop-Off'... Sentenced to 2 Years and 6 Months
- Idol Member Posts Letter Saying "Suspending Activities Due to Pregnancy"... Turns Out She's AI?
On the 17th, SK Bioscience announced that it had received approval from the U.S. Food and Drug Administration (FDA) for the Phase 3 clinical trial plan of the 21-valent pneumococcal vaccine, which is being developed in collaboration with Sanofi. The global clinical trial, recruiting 7,700 participants worldwide, began dosing its first subject last month.
![[Featured Stock] SK Bioscience Rises on US Clinical Phase 3 Approval for Pneumococcal Vaccine](http://www.asiae.co.kr/news/img_view.htm?img=2024072208164559128_1721603806.jpg)
© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.
